Trusted Resources: Education
Scientific literature and patient education texts
Evolving Landscape in the Management of Transthyretin Amyloidosis
source: Annals of Medicine
year: 2015
authors: Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB
summary/abstract:Transthyretin (TTR) amyloidosis (ATTR amyloidosis) is a multisystemic, multigenotypic disease resulting from deposition of insoluble ATTR amyloid fibrils in various organs and tissues. Although considered rare, the prevalence of this serious disease is likely underestimated because symptoms can be non-specific and diagnosis largely relies on amyloid detection in tissue biopsies. Treatment is guided by which tissues/organs are involved, although therapeutic options are limited for patients with late-stage disease. Indeed, enthusiasm for liver transplantation for familial ATTR amyloidosis with polyneuropathy was dampened by poor outcomes among patients with significant neurological deficits or cardiac involvement.
Hence, there remains an unmet medical need for new therapies. The TTR stabilizers tafamidis and diflunisal slow disease progression in some patients with ATTR amyloidosis with polyneuropathy, and the postulated synergistic effect of doxycycline and tauroursodeoxycholic acid on dissolution of amyloid is under investigation.
Another therapeutic approach is to reduce production of the amyloidogenic protein, TTR. Plasma TTR concentration can be significantly reduced with ISIS-TTRRx, an investigational antisense oligonucleotide-based drug, or with patisiran and revusiran, which are investigational RNA interference-based therapeutics that target the liver. The evolving treatment landscape for ATTR amyloidosis brings hope for further improvements in clinical outcomes for patients with this debilitating disease.
organization: University College, UK; Kumamoto University, Japan; Mayo Clinic, USA; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico; Université Paris-Sud, France; Umeå University, SwedenDOI: 10.3109/07853890.2015.1068949
read more full text
Related Content
-
The Patient Journey Toward a Diagnosis of Hereditary Transthyretin (ATTRv) AmyloidosisBackground: Despite emerging treatments...
-
Heart Failure Diet: Sodium and Heart FailureHeart Failure Diet Resources and answer...
-
Michael Alan Rosenzweig, MD, MSMichael Alan Rosenzweig is an Associate ...
-
Q&A: Fatigue, Amyloid Presence in Bone Marrow, CAR-T – ASG Webinar 13/13https://www.youtube.com/watch?v=4gUXPbOk...
-
Peripheral Neuropathy Symptoms, Diagnostic Tests, and Approved Treatments – ASG Webinar 7/11https://www.youtube.com/watch?v=K2TmwAfu...
-
ISA 2020 | AL Amyloidosis: Multidisciplinary Treatment Approachhttps://www.youtube.com/watch?time_conti...
-
Cardiac Amyloidosis – Tests and Assessmenthttps://www.youtube.com/watch?v=9gIB40Im...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.